Department of Sociology, University of Warwick, Coventry CV4 7AL.
Sociol Health Illn. 2011 Jul;33(5):710-25. doi: 10.1111/j.1467-9566.2011.01320.x. Epub 2011 Mar 4.
Drawing on insights from both medical sociology and science and technology studies this article provides a critical analysis of the nature and status of pharmaceuticalisation in terms of the following key dimensions and dynamics: (i) the redefinition or reconfiguration of health 'problems' as having a pharmaceutical solution; (ii) changing forms of governance; (iii) mediation; (iv) the creation of new techno-social identities and the mobilisation of patient or consumer groups around drugs; (v) the use of drugs for non-medical purposes and the creation of new consumer markets; and, finally, (vi) drug innovation and the colonisation of health futures. Pharmaceuticalisation, we argue, is therefore best viewed in terms of a number of heterogeneous socio-technical processes that operate at multiple macro-levels and micro-levels that are often only partial or incomplete. The article concludes by drawing out some broader conceptual and reflexive issues this raises as to how we might best understand pharmaceuticalisation, based on our analysis, as a framework for future sociological work in this field.
本文借鉴医学社会学和科学技术研究的观点，从以下关键维度和动态对制药的性质和地位进行了批判性分析：（i）将健康“问题”重新定义或重新配置为具有药物解决方案；（ii）治理形式的变化；（iii）调解；（iv）新技术社会身份的创造以及围绕药物动员患者或消费者群体；（v）出于非医疗目的使用药物和创造新的消费市场；最后，（vi）药物创新和健康未来的殖民化。我们认为，制药化最好被视为在多个宏观和微观层面上运作的一系列异质的社会技术过程，这些过程往往是局部的或不完整的。本文最后通过提出一些更广泛的概念和反思性问题，就如何根据我们的分析，将制药化作为该领域未来社会学工作的框架，最好地理解制药化问题，得出了一些结论。
